Advancements in Treatment Strategies for HER2+ Metastatic Breast Cancer: Insights from Experts at the Duke Cancer Center : Episode 2

Approaches for 1L Therapy and Restaging in Triple-Positive mBC

January 5, 2024

By Carey K. Anders, MD
Heather Moore, CPP, PharmD

Opinion

Video

Susan Dent, MD, delves into the exploration of front-line treatment options for triple-positive breast cancer and examines strategies for restaging in the event of disease progression after first-line therapy.

EP: 1.Advancements in Treatment Strategies for HER2+ Metastatic Breast Cancer: Insights from Experts at the Duke Cancer Center

EP: 2.Approaches for 1L Therapy and Restaging in Triple-Positive mBC

EP: 3.The Role of Radiotherapy in HER2+ mBC

EP: 4.Treatment Approaches for Triple-Positive mBC in the 2L Setting and Beyond

EP: 5.Treatment Considerations and AE Management Strategies with HER2-Directed Therapies

EP: 6.Patient Case Presentation: A 34-Year-Old Woman with HER2+ mBC and Brain Metastases

EP: 7.HER2CLIMB: Targeting Stable and Active Brain Metastases in Advanced HER2+ Breast Cancer

EP: 8.BRIDGET: Preventing Secondary Brain Metastases in Advanced HER2+ Breast Cancer

EP: 9.Strategies for AE Management with Tucatinib in Breast Cancer

EP: 10.D-TORCH: Topical Diclofenac for Reducing Hand Foot Syndrome with Capecitabine

EP: 11.Patient Case Presentation: A 34-Year-Old Woman with HER+ mBC and Brain Metastases

EP: 12.Advancements in Treating Brain Metastases in HER2+ Breast Cancer

EP: 13.Radiation Necrosis with ADCs and Concurrent Radiotherapy for Brain Metastases

EP: 14.Strategies for AE Management with T-DXd in Breast Cancer

EP: 15.Looking Ahead: Future Perspectives and Unmet Need in HER+ Breast Cancer

EP: 16.Recent Data from KATHERINE and APHINITY in HER2+ Breast Cancer

EP: 17.Updates from HER2CLIMB in HER2+ Metastatic Breast Cancer

EP: 18.BRIDGET Study: Tucatinib Plus HER2-Directed Antibody Therapy in Breast Cancer

EP: 19.Future Perspectives on HER2+ Breast Cancer Treatment

EP: 20.Applying Updated Findings From SABCS 2023 to HER2+ Breast Cancer Practice

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos

Related Content

61 Can the Use of Tumor Margin Markers for Intraoperative Specimen Radiographs Decrease the Rate of Margin Positivity During Breast Conservation Therapy?

61 Can the Use of Tumor Margin Markers for Intraoperative Specimen Radiographs Decrease the Rate of Margin Positivity During Breast Conservation Therapy?

Camila Ortega;Micah Brainerd;Christopher Mamone;Caroline Mangira;Andrew Fenton;Mary Murray

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS

April 21st 2025

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

64 A Prospective Study to Accurately Define the Nipple-Ward Margins in Patients Undergoing Lumpectomy for Breast Cancer

64 A Prospective Study to Accurately Define the Nipple-Ward Margins in Patients Undergoing Lumpectomy for Breast Cancer

Susan Laura Jao;Fardeen Bhimani;Arianna Cavalli;Bryan Harmon;Maureen McEvoy;Ethan Ravetch;Michelle Sheckley;Anjuli Gupta;Sheldon Feldman

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD

January 13th 2025

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Ten-year data from the phase 3 APHINITY trial will be presented at the 2025 European Society for Medical Oncology (ESMO) Breast Cancer Congress.

Pertuzumab Combo Reduces Risk of Death in HER2+ Early-Stage Breast Cancer

Roman Fabbricatore

Ten-year data from the phase 3 APHINITY trial will be presented at the 2025 European Society for Medical Oncology Breast Cancer Congress.

65 The Outcomes of Nipple Sparing Goldilocks Mastectomy in a Primarily Overweight and Obese Population

65 The Outcomes of Nipple Sparing Goldilocks Mastectomy in a Primarily Overweight and Obese Population

Allen Gee;Grace Oh;June Lee

Related Content

61 Can the Use of Tumor Margin Markers for Intraoperative Specimen Radiographs Decrease the Rate of Margin Positivity During Breast Conservation Therapy?

61 Can the Use of Tumor Margin Markers for Intraoperative Specimen Radiographs Decrease the Rate of Margin Positivity During Breast Conservation Therapy?

Camila Ortega;Micah Brainerd;Christopher Mamone;Caroline Mangira;Andrew Fenton;Mary Murray

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS

April 21st 2025

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

64 A Prospective Study to Accurately Define the Nipple-Ward Margins in Patients Undergoing Lumpectomy for Breast Cancer

64 A Prospective Study to Accurately Define the Nipple-Ward Margins in Patients Undergoing Lumpectomy for Breast Cancer

Susan Laura Jao;Fardeen Bhimani;Arianna Cavalli;Bryan Harmon;Maureen McEvoy;Ethan Ravetch;Michelle Sheckley;Anjuli Gupta;Sheldon Feldman

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD

January 13th 2025

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Ten-year data from the phase 3 APHINITY trial will be presented at the 2025 European Society for Medical Oncology (ESMO) Breast Cancer Congress.

Pertuzumab Combo Reduces Risk of Death in HER2+ Early-Stage Breast Cancer

Roman Fabbricatore

Ten-year data from the phase 3 APHINITY trial will be presented at the 2025 European Society for Medical Oncology Breast Cancer Congress.

65 The Outcomes of Nipple Sparing Goldilocks Mastectomy in a Primarily Overweight and Obese Population

65 The Outcomes of Nipple Sparing Goldilocks Mastectomy in a Primarily Overweight and Obese Population

Allen Gee;Grace Oh;June Lee

OncNursingNews.com

TargetedOnc.com

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.